Member Info for Hall123

New reply.

I am glad nuvec uses MSNs

Why I think Nuvec will reach use In humans.

MSNs have several advantages over other nanoparticle-based vaccine delivery systems, such as cationic lipid nanoparticles (CLNs). MSNs have a larger surface area, which allows for more efficient loading of vaccine antigens. MSNs are also biocompatible and biodegradable, which reduces the risk of toxicity and long-term accumulation in the body. Additionally, MSNs can be easily functionalized with targeting ligands or adjuvants, which can enhance the immune response to vaccine antigens. These unique properties make MSNs an attractive platform for vaccine delivery, and Nuvec is at the forefront of developing this technology for human use.

My mistake on that part. Thanks Leister. Still learning every day.

Hello again Vander.
Nuvec is not related to MSNs. It is a different type of nanoparticle-based vaccine delivery platform that uses cationic lipid nanoparticles (CLNs) instead of MSNs.
CLNs have a positive surface charge that allows them to interact with negatively charged cell membranes, facilitating uptake and delivery of the vaccine payload.

I feel you are trying to put N4pharma down without properly researching its products and how they work.

CLNs (which Nuvec uses as a delivery platform) have been used in several clinical trials as a vaccine delivery platform. For example, a COVID-19 vaccine that uses CLNs as a delivery vehicle is currently being evaluated in clinical trials. CLNs have also been used in preclinical models to deliver a variety of other vaccines and therapeutic agents.

Hall

That's it Leister. I'm not here only for the commercial deal. I am here for the tick box journey on the way!

It's certainly coming together.

Hi Dan.
Getting to a commercial deal or partnership requires following a path which ticks certain boxes that attracts interest from a consumer (commercial deal or partnership).
N4pharma are following this path and starting to pick up some great speed down it. Which is extremely positive.
Imo we are looking for the clinical trials to start before we look at a commercial deal.
The process is being followed and money looks good.

Shouldn't be long now.

There are other similar technologies to Nuvec that have been taken to clinical trials. For example, Acuitas Therapeutics has developed a lipid nanoparticle delivery system that has been used in clinical trials for the delivery of RNA-based medicines. Additionally, Arbutus Biopharma has developed a lipid nanoparticle delivery system that has been used in clinical trials for the delivery of RNA-based medicines, including a COVID-19 vaccine.

Nuvec is a different technology than MSNs conjugated with PEI. Nuvec is a silica nanoparticle-based delivery system that can be used to deliver a variety of drugs, including nucleic acids like DNA and RNA. The Nuvec particles are designed to be biocompatible and to protect the drug cargo from degradation in the body. While Nuvec and MSNs conjugated with PEI both have the potential to improve the delivery of drugs like siRNA, they are distinct technologies with different properties and mechanisms of action.

There have been preclinical studies that suggest that this approach may be safe and effective for delivering drugs to tumors. In order to conduct a first-in-human trial, researchers would need to provide evidence of the safety and efficacy of the treatment in animal models, as well as data about the drug's pharmacokinetics and pharmacodynamics. Additionally, researchers may need to provide information about the drug's chemical structure and manufacturing process.

One of the advantages of using MSNs conjugated with PEI for delivering siRNA is that they can improve the stability and delivery of the siRNA to its target cells. MSNs are biocompatible and can be easily modified to carry different types of drugs or molecules, including siRNA. PEI, on the other hand, can help to protect the siRNA from degradation and facilitate its uptake by cells. Additionally, MSNs can be engineered to target specific cells or tissues, which can help to minimize off-target effects and improve the efficacy of the treatment.

Hall

Based on preclinical studies, Nuvec appears to have several advantages over other non-viral gene therapy delivery systems. For example, Nuvec has been shown to be highly efficient at delivering genetic material to cells, with a low toxicity profile. Additionally, Nuvec is relatively easy and inexpensive to produce, which could make it more accessible for researchers and clinicians.

While it's still early in the development process, these preliminary results suggest that Nuvec has the potential to be a highly effective and safe gene therapy delivery system.

Brilliant News. Loving the consistent updates and progression.

Results are there and extremely positive.

Very happy with the update. Looks good!

Plenty of short term and long term news to come according to Nigel in the latest interview.
Bargain at these prices !!

We all know it goes up just at fast.

I agree Homer. The market would gain great confidence with a director buy.

Can see the sp rising this week.
Plenty of news due very soon plus lots in the pipeline for this year .

Take away the spaces on the middle.

BRILLIANT !! Much more confident!

https://www.directors talkinterviews.com/n4-pharma-ceo-nigel-theobald-excited-with-sirna-programme-video/4121109771

Can't see anyone selling with the future projection.

Looks like a hint to me.
Happy we still have our MTA, that must mean progress.
Cash Is certainly looking good.

All good !!